Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors
Restricted accessResearch articleFirst published online September, 2011
Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: Clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors
Somatostatin receptor scintigraphy (SRS) is the standard method for the detection of somatostatin receptors (SSTRs). It is commonly used in gastroenteropancreatic neuroendocrine tumor (GEP-NET) staging, and represents the criterion of choice for treatment with somatostatin (SST) analogs. Immunohistochemistry (IHC) was reported as a reliable method for the detection of SSTRs with theoretically superior sensitivity over SRS.
Methods and study design
We retrospectively analyzed the sensitivity and specificity of IHC in the detection of SSTRs in a cohort of consecutive patients with GEP-NETs attending our Institute from 1997 to 2007. IHC analysis was restricted to SSTR2 and SSTR5, and the results were interpreted according to two different scoring systems. SRS was used as the gold standard.
Results
Forty-four patients were enrolled; 24 (55%) had foregut carcinoids, 9 (20%) midgut carcinoids, 2 (5%) hindgut carcinoids, and 9 (20%) had GEP-NETs of unknown primary sites. A high concordance rate between IHC and SRS was shown, irrespective of the IHC scoring system applied (73% and 70%). The sensitivity of IHC was 89.3% and 78.6% and the specificity 43.8% and 50%, depending on the scoring system used.
Conclusions
Although SSTR2 was shown to be expressed by IHC in up to 50% of tumors not visualized by SRS, SRS still remains the method of choice in the diagnostic and therapeutic management of GEP-NETs. More pathological and clinical data are needed to properly understand the clinical relevance of immunohistochemical detection of SSTR expression in the absence of tumor uptake at SRS.
YamadaY., PostS.R., WangK., TagerH.S., BellG.I., SeinoS.: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.Proc Natl Acad Sci, 89: 251–255, 1992.
2.
YamadaY., ReisineT., LawS.F., IharaY., KubotaA., KagimotoS., SeinoM., SeinoY., BellG.I., SeinoS.: Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase.Mol Endocrinol, 6: 2136–2142, 1992.
3.
YamadaY., KagimotoS., KubotaA., YasudaK., MasudaK., SomeyaY., IharaY., LiQ., ImuraH., SeinoS., SeinoY.: Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.Biochem Biophys Res Commun, 195: 844–852, 1993.
4.
PapottiM., BongiovanniM., VolanteM., AllìaE., LandolfiS., HelboeL., SchindlerM., ColeS., BussolatiG.: Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors.Virchows Arch, 440: 461–475, 2002.
5.
KubotaA., YamadaY., KagimotoS., ShimatsuA., ImamuraM., TsudaK., ImuraH., SeinoS., SeinoY.: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors.J Clin Invest, 93: 1321–1325, 1994.
6.
JansonE.T., GoblA., KälknerK.M., ObergK.: A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients.Cancer Res, 56: 2561–2565, 1996.
7.
JansonE.T., StridsbergM., GoblA., WestlinJ.E., ObergK.: Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies.Cancer Res, 58: 2375–2378, 1998.
8.
JohnM., MeyerhofW., RichterD., WaserB., SchaerJ.C., ScherüblH., Boese-LandgrafJ., NeuhausP., ZiskeC., MöllingK., RieckenE.O., ReubiJ.C., WiedenmannB.: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.Gut, 38: 33–39, 1996.
9.
LambertsS.W.J., KrenningE.P., ReubiJ.C.: The role of somatostatin and its analogs in the diagnosis and treatment of tumors.Endocr Rev, 12: 450–482, 1991.
10.
HoflandL.J., LambertsS.W., van HagenP.M., ReubiJ.C., SchaefferJ., WaaijersM., van KoetsveldP.M., SrinivasanA., KrenningE.P., BreemanW.A.: Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1] octreotide in somatostatin receptor-positive organs.J Nucl Med, 44: 1315–1321, 2003.
11.
ObergK., KvolsL., CaplinM., Delle FaveG., de HerderW., RindiG., RuszniewskiP., WolteringE.A., WiedenmannB.: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.Ann Oncol, 15: 966–973, 2004.
12.
Van EssenM., KrenningE.P., De JongM., ValkemaR., KwekkeboomD.J.: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.Acta Oncol, 46: 723–734, 2007.
13.
ReubiJ.C., SchärJ.C., WaserB., WengerS., HeppelerA., SchmittJ.S., MäckeH.R.: Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.Eur J Nucl Med, 27: 273–282, 2000.
14.
JansonE.T., WestlinJ.E., ErikssonB., AhlströmH., NilssonS., ObergK.: [111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.Eur J Endocr, 131: 577–581, 1994.
15.
ChitiA., BrigantiV., FantiS., MonettiN., MasiR., BombardieriE.: Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.Q J Nucl Med, 44: 42–49, 2000.
16.
LebtahiR., CadiotG., SardaL., DaouD., FaraggiM., PetegniefY., MignonM., le GuludecD.: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.J Nucl Med, 38: 853–858, 1997.
17.
KulaksizH., EisseleR., RösslerD., SchulzS., HölltV., CetinY., ArnoldR.: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.Gut, 50: 52–60, 2002.
LambertsS.W.J., ReubiJ.C., KrenningE.P.: Somatostatin and the concept of peptide receptor scintigraphy in oncology.Semin Oncol, 21(Suppl 13): 1–5, 1994.
20.
KrenningE.P., KwekkeboomD.J., de JongM., VisserT.J., ReubiJ.C., BakkerW.H., KooijP.P., LambertsS.W.: Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.Semin Oncol, 21(Suppl 13): 6–14, 1994.
21.
GabrielM., DecristoforoC., DonnemillerE., UlmerH., Watfah RychlinskiC., MatherS.J., MoncayoR.: An intrapatient comparison of 99mTc-EDDA/HYNICTOC with 111In-DT-PA-octreotide for diagnosis of somatostatin receptor-expressing tumors.J Nucl Med, 44: 708–716, 2003.
22.
VolanteM., BrizziM.P., FaggianoA., La RosaS., RapaI., FerreroA., MansuetoG., RighiL., GaranciniS., CapellaC., De RosaG., DogliottiL., ColaoA., PapottiM.: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.Mod Pathol, 20: 1172–1182, 2007.
23.
SolciaE., KlöppelG., SobinL.H.: Histological typing of endocrine tumors. In: WHO international histological classification of tumors, 2nd edition, pp 61–68, Springer Verlag, Berlin, 2000.
24.
KimuraN., PilichowskaM., DateF., KimuraI., SchindlerM.: Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.Clin Cancer Res, 5: 3483–3487, 1999.
25.
ReubiJ.C., KappelerA., WaserB., LaissueJ., HipkinR.W., SchonbrunnA.: Immunohistochemical localization of somatostatin receptors sst2A in human tumors.Am J Pathol, 153: 233–245, 1998.
26.
SchulzS., HelmholzT., SchmittJ., FrankeK., OttoH.J., WeiseW.: True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.Breast Cancer Res Treat, 72: 221–226, 2002.
27.
PapottiM., CroceS., BellòM., BongiovanniM., AllìaE., SchindlerM., BussolatiG.: Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours.Virchows Arch, 439: 787–797, 2001.
28.
HoflandL.J., LambertsS.W.J.: The pathophysiological consequences of somatostatin receptor internalization and resistance.Endocr Rev, 24: 28–47, 2003.
29.
HillmanN., HerranzL., AlvarezC., Martìnez OlmosM.A., MàrcoA., Gòmez-PanA.: Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).Exp Clin Endocrinol Diabetes, 106: 226–230, 1998.
